International Launch Of Acculis Microwave Tissue Ablation System For The Coagulation Of Soft Tissue In Open Surgery
DENMEAD, England--(BUSINESS WIRE)--Acculis Limited, the leading UK microwave ablation system company, today announced the international release of their pioneering Microwave Tissue Ablation system for the coagulation of soft tissue in open surgery. The FDA 510(k) cleared device is the first microwave ablation system to offer large fast spherical ablations from single needle placements, superseding the performance of lower power RF or other current microwave ablation systems.
This launch follows the initial distribution in January 2008 to 14 leading cancer centres in the USA, UK, Europe and Australia. The second stage entails a further 30 cancer centers throughout the world who will collaborate along with the phase one cohort in an audit of clinical use of the system and centralizing patient and treatment data. This clinical activity is being overseen by AUGIS the UK HPB Surgeons body.
David M. Lloyd, Consultant Liver Surgeon at Leicester Royal Infirmary who developed the microwave ablation machine and the first to use the system in the UK said "The Acculis MTA System allows us to treat tumours in the liver quickly and decisively using a single probe. In some cases we are now able to treat tumours which otherwise would have been inoperable. This is a significant advance in the treatment of cancer. The Acculis system appears to offer more effective treatment of liver tumours than lower power RF or current microwave ablation systems."
Stuart McIntyre, CEO of Acculis Limited said "We are pleased to be making this market leading technology available to cancer centers throughout the world. Our system is the first to meet surgeons needs for 5cm spherical ablations in 4 minutes without the need for complex multi needle placements. This is just the first in a line of products that exploit our proven 2.45gHz and 9.2gHz microwave platforms."
The system offers large, fast and predictable performance with the ease of use associated with single needle systems. The speed and predictability means that the desired coagulation zone can be reliably and decisively achieved, and the short time taken to create large coagulations means that many more sites can be coagulated within a given operative window. The simplicity of the system ensures that ablations can be performed during open procedures without placing complex additional equipment management demands on the operative team.
Acculis is a specialist medical device company developing microwave energy ablation systems for oncology applications. Acculis is part of the Microsulis group of companies. Microsulis and Acculis are based in Hampshire, England. For more information about the Acculis MTA System, visit www.acculis.com, www.microsulis.com. Acculis MTA – Fast, Large, Simple, Predictable
Copyright 2008 Business Wire All Rights Reserved.